IL254435B2 - COMBINATION OF BTK INHIBITOR, mTOR KINASE INHIBITOR AND IMMUNOMODULATORY DRUG AND USE THEREFOR TO TREAT LYMPHOID MALIGNANCY - Google Patents

COMBINATION OF BTK INHIBITOR, mTOR KINASE INHIBITOR AND IMMUNOMODULATORY DRUG AND USE THEREFOR TO TREAT LYMPHOID MALIGNANCY

Info

Publication number
IL254435B2
IL254435B2 IL254435A IL25443517A IL254435B2 IL 254435 B2 IL254435 B2 IL 254435B2 IL 254435 A IL254435 A IL 254435A IL 25443517 A IL25443517 A IL 25443517A IL 254435 B2 IL254435 B2 IL 254435B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
btk
avg
Prior art date
Application number
IL254435A
Other languages
English (en)
Hebrew (he)
Other versions
IL254435B1 (en
IL254435A0 (en
Original Assignee
Zhejiang Dtrm Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Dtrm Biopharma Co Ltd filed Critical Zhejiang Dtrm Biopharma Co Ltd
Publication of IL254435A0 publication Critical patent/IL254435A0/en
Publication of IL254435B1 publication Critical patent/IL254435B1/en
Publication of IL254435B2 publication Critical patent/IL254435B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL254435A 2015-03-19 2016-03-18 COMBINATION OF BTK INHIBITOR, mTOR KINASE INHIBITOR AND IMMUNOMODULATORY DRUG AND USE THEREFOR TO TREAT LYMPHOID MALIGNANCY IL254435B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510119944.5A CN106146508A (zh) 2015-03-19 2015-03-19 优化的联合用药及其治疗癌症和自身免疫疾病的用途
PCT/CN2016/000149 WO2016145935A1 (zh) 2015-03-19 2016-03-18 优化的联合用药及其治疗癌症和自身免疫疾病的用途

Publications (3)

Publication Number Publication Date
IL254435A0 IL254435A0 (en) 2017-11-30
IL254435B1 IL254435B1 (en) 2024-03-01
IL254435B2 true IL254435B2 (en) 2024-07-01

Family

ID=56918303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254435A IL254435B2 (en) 2015-03-19 2016-03-18 COMBINATION OF BTK INHIBITOR, mTOR KINASE INHIBITOR AND IMMUNOMODULATORY DRUG AND USE THEREFOR TO TREAT LYMPHOID MALIGNANCY

Country Status (11)

Country Link
EP (1) EP3272752A4 (enExample)
JP (2) JP7012534B2 (enExample)
KR (2) KR102428387B1 (enExample)
CN (4) CN106146508A (enExample)
AU (2) AU2016232923B2 (enExample)
BR (1) BR112017019790B1 (enExample)
CA (2) CA2980016C (enExample)
EA (2) EA037058B1 (enExample)
IL (1) IL254435B2 (enExample)
MX (1) MX2017011836A (enExample)
WO (1) WO2016145935A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
JP6782855B2 (ja) * 2016-11-15 2020-11-11 杭州和正医薬有限公司 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用
CN106831788B (zh) * 2017-01-22 2020-10-30 鲁南制药集团股份有限公司 伊布替尼精制方法
MA50256A (fr) * 2017-09-15 2020-07-22 Aduro Biotech Inc Composés de pyrazolopyrimidinone et leurs utilisations
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
WO2019148150A1 (en) * 2018-01-29 2019-08-01 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN108992454B (zh) * 2018-06-20 2020-06-02 合肥医工医药股份有限公司 一种治疗皮肤炎症性疾病的复方药物组合物
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
KR102819183B1 (ko) * 2019-03-29 2025-06-13 한미약품 주식회사 퓨로피리미딘 화합물의 산 부가염의 결정형
CA3153456A1 (en) 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
CN110845500B (zh) * 2019-10-09 2021-05-11 清华大学 靶向btk降解化合物在治疗自身免疫系统疾病中的应用
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
EP4171556A1 (en) * 2020-06-25 2023-05-03 Tolremo Therapeutics AG A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
CN116615425A (zh) * 2020-09-17 2023-08-18 诺华股份有限公司 作为Sppl2a抑制剂的化合物和组合物
CN114507236A (zh) * 2022-02-28 2022-05-17 山东中医药大学 mTOR蛋白降解靶向嵌合体及其制备方法和应用
WO2023197914A1 (zh) * 2022-04-12 2023-10-19 安徽中科拓苒药物科学研究有限公司 一种吡唑并嘧啶类化合物的新用途
CN117045800A (zh) * 2022-05-06 2023-11-14 上海科技大学 mTOR抑制剂增强靶向蛋白降解药物功效的应用
CN116024346A (zh) * 2023-02-10 2023-04-28 复旦大学附属华山医院 SLCO1B1 rs2306283位点多态性在评价甲氨蝶呤所致骨髓抑制发生风险中的应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CA3001152A1 (en) * 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP3311818A3 (en) * 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
SI2710005T1 (sl) * 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
EP2731612A4 (en) * 2011-07-13 2015-04-08 Pharmacyclics Inc BRUTON TYROSINE KINASE HEMMER
CN104487441B (zh) * 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
AU2013296627C9 (en) * 2012-07-30 2018-03-22 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
WO2014022569A1 (en) * 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
KR102229478B1 (ko) * 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6389241B2 (ja) * 2013-04-17 2018-09-12 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
CN105408334B (zh) * 2013-05-21 2017-10-10 江苏迈度药物研发有限公司 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLOCKSIDGE, JEMMA, ET AL., CC-122 HAS ROBUST ANTI-PROLIFERATIVE ACTIVITY IN A PRIMARY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CO-CULTURE MODEL AND IS SUPERIOR TO LENALIDOMIDE., 31 December 2014 (2014-12-31) *
EZELL SA, ET AL., SYNERGISTIC INDUCTION OF APOPTOSIS BY COMBINATION OF BTK AND DUAL MTORC1/2 INHIBITORS IN DIFFUSE LARGE B CELL LYMPHOMA., 31 July 2014 (2014-07-31) *
MATHEWS LAG, ET AL., HIGH-THROUGHPUT COMBINATORIAL SCREENING IDENTIFIES DRUGS THAT COOPERATE WITH IBRUTINIB TO KILL ACTIVATED B-CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA CELLS, 27 January 2014 (2014-01-27) *
NIH. US NATIONAL LIBRARY OF MEDICINE. CLINICALTRIALS.GOV., A PHASE 1/2, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE CC-122 IN COMBINATION WITH IBRUTINIB AND OBINUTUZUMAB IN SUBJECTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (ENHANCE), 2 April 2015 (2015-04-02) *
PATRICK R. HAGNER, ET AL., CC-122, A PLEIOTROPIC PATHWAY MODIFIER, MIMICS AN INTERFERON RESPONSE AND HAS ANTITUMOR ACTIVITY IN DLBCL, 22 May 2015 (2015-05-22) *
PETER H SCHAFER ET AL., TARGETING CEREBLON WITH THE HIGH AFFINITY IMMUNOMODULATORY COMPOUND CC-220: A NOVEL THERAPEUTIC AGENT FOR B CELL DYSCRASIAS, 16 November 2012 (2012-11-16) *
REEDER CB, ET AL, NOVEL THERAPEUTIC AGENTS FOR B-CELL LYMPHOMA: DEVELOPING RATIONAL COMBINATIONS, 26 October 2010 (2010-10-26) *

Also Published As

Publication number Publication date
JP2022003103A (ja) 2022-01-11
EP3272752A1 (en) 2018-01-24
CA2980016C (en) 2023-04-11
AU2016232923B2 (en) 2020-08-27
KR20220110872A (ko) 2022-08-09
AU2016232923A1 (en) 2017-10-05
JP7012534B2 (ja) 2022-02-14
BR112017019790B1 (pt) 2023-11-07
CN106146508A (zh) 2016-11-23
WO2016145935A1 (zh) 2016-09-22
IL254435B1 (en) 2024-03-01
BR112017019790A2 (pt) 2018-05-22
EA037058B1 (ru) 2021-02-01
CN111349099A (zh) 2020-06-30
IL254435A0 (en) 2017-11-30
AU2020277128A1 (en) 2020-12-24
CN107406454A (zh) 2017-11-28
CN114790209A (zh) 2022-07-26
KR20170129733A (ko) 2017-11-27
MX2017011836A (es) 2017-12-07
EP3272752A4 (en) 2018-10-31
EA202092671A1 (ru) 2021-03-31
KR102428387B1 (ko) 2022-08-02
CN107406454B (zh) 2020-05-19
EA201792066A1 (ru) 2018-03-30
AU2020277128B2 (en) 2022-12-22
JP2018512413A (ja) 2018-05-17
CA2980016A1 (en) 2016-09-22
CA3191171A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
AU2020277128B2 (en) Optimised combination therapy and use thereof to treat cancer and autoimmune disease
US11369620B2 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
JP6916796B2 (ja) Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
WO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
CA3108449A1 (en) Optically active bridged piperidine derivative
WO2020030925A1 (en) Heterocyclic substituted ureas, for use against cancer
HK1241869A1 (en) Optimised combination therapy and use thereof to treat cancer and autoimmune disease
WO2025038815A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
CN116490507A (zh) 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CN117440813A (zh) 治疗脑或cns的癌转移的egfr降解剂
WO2025059027A1 (en) Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors